BioAge, Obesity
Obesity drug developer BioAge Labs aims up to $640 million valuation in upsized US IPO
(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
BioAge, obesity drug developer, upsizes proposed IPO
BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed initial public offering to approximately $189M. In a recent SEC filing,
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
Obesity drug developer BioAge seeks up to $587 mln valuation in US IPO
Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.
Weight loss drug developer BioAge seeks up to $602M valuation in U.S. IPO
Obesity drug developer BioAge Labs (BIOA) files for U.S. IPO to offer 7.5M shares at $17-$19 implying valution of up to $602M. Read more here/
Obesity drugmaker BioAge targets $158 million in IPO
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday
Obesity drug developer BioAge Labs targets up to $640 mln valuation in upsized US IPO
BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong demand from investors.
Drugmaker seeks $157.5M in IPO, placement
BioAge Labs, a clinical-stage biotech firm focused on obesity and metabolic disease therapies, aims to raise up to $157.5 million through its initial public offering and private placement, Bloomberg reported Sept. 18. The company plans to offer 7.5 million shares priced between $17 and $19 each, according to a filing with the Securities and Exchange Commission. At the top of the price range, BioAge's market valuation could reach $587 million. Previously, the company had a valuation of $394 million after raising $194 million in a Series D funding round in February.
FierceBiotech9h
BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the ...
Bioage Labs, Inc IPOs Tomorrow, Here's What You Need To Know
BioAge Labs, Inc BIOA IPO will take place September, 26 on the NASDAQ exchange under the ticker BIOA. The company is offering shares at an expected price between $17.00 and $19.00 per share with an ...
Ziarul BURSA | BURSA.RO3d
BioAge wants to raise $158 million through IPO
BioAge Labs Inc., an American clinical-stage biotech company developing therapies for obesity and metabolic diseases, is ...
Seeking Alpha20d
BioAge Labs Readies $100 Million IPO Plan For Obesity Treatment
A Quick Take On BioAge Labs, Inc. BioAge Labs, Inc. (BIOA) has filed to raise $100 million in an IPO of its common stock, according to SEC S-1 registration information. The company is a clinical ...
Crain's Chicago Business21h
Commercial retail REIT FrontView seeks $277M in IPO
The Dallas-based company focuses on so-called outparcels, properties that point directly onto high-traffic roads that are visible to consumers, and Illinois is its largest market.
Benzinga.com21d
BioAge Labs Files For $100M IPO, Becomes The New Entrant In Obesity Drugs Race
The company's lead drug Azelaprag has been well-tolerated in 265 individuals across eight Phase 1 trials. The STRIDES clinical trial will assess azelaprag with Eli Lilly's Zepbound, with topline ...